Hepatocellular carcinoma: Epidemiological profile from a cohort of federal employees in Mexico
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 3
Abstract
Introduction. Hepatocellular carcinoma (HCC) has become a frequent type of cancer in Mexico. At the present time it represents the 19th cause of death in the population. Objective. To recognize the epidemiological profile and the treatment results in a cohort of federal employees with HCC. Material and methods. We analyzed 47 consecutive cases with HCC diagnosis from January 2004 till December 2007. Twenty four demographic data, tumor staging, clinical, and biochemical variables were analyzed to identify parameters predicting surviva by computing Kaplan-Mier and Mantel-Cox survival curves. Results. Patient reference increased 5% each year. The mean age was 60.4 years, 63.8% female sex, and 72.3% had cirrhosis, 44.7% had Hepatitis C infection. Most patients presented with advanced disease: 55.3% were AJCC stage 3 and 21.3% stage 4, 51.1% were BCLC class D. Mean tumor size was 8.09 cm. Median survival time from diagnosis was 122 days. Patients that did not receive treatment had a median survival of 70 days; the longest survival of patients was of those that received transarterial chemoembolization with a median of 707 days, followed by surgery with 683 days. Univariate analysis showed survival was associated to MELD score, AJCC and BCLC staging, creatinine level and ascites. Multivariate analysis showed tumor differentiation, AJCC staging and the choice of treatment to be related to the risk of death. Conclusion. An increase in the referral of HCC was demonstrated. Most patients had cirrhosis and HCV infection. Due to advance disease staging, TACE was the treatment that offered longest survival
Authors and Affiliations
Laura Ladrón de Guevara, Paulo Rojas-Macuil, Xochiquetzal Sánchez-Chávez, Alejandro Rossano-García, Ma. Teresa Gorraez-de-la-Mora, Guadalupe Cervantes-Sánchez, Julita Orozco-Vázquez, Mario Lemus- Velázquez, Leticia Rosas-Zúñiga, Aura Erazo-Valle, Mauricio Di-Silvio
Keywords
Related Articles
- EP ID EP77868
- DOI -
- Views 102
- Downloads 0
A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV
Objectives. Filibuvir is a non-nucleoside inhibitor of hepatitis C virus (HCV) polymerase. This study evaluated the safety and efficacy of filibuvir plus pegylated interferon alfa-2a (pegIFN)/ribavirin. Material and meth...
Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study
[sup][/sup] Introduction and aim. Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free water excre...
Predictive role BLVRA mRNA expression in hepatocellular cancer
Introduction and aim. Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor. It is primarily causedby hepatic cirrhosis or chronic viral hepatitis. Hepatic carcinogenesis is associated with inc...
Kava hepatotoxicity - a clinical review
This review critically analyzes the clinical data of patients with suspected kava hepatotoxicity and suggests recommendations for minimizing risk. Kava is a plant (Piper methysticum) of the pepper family Piperaceae, and...
Swallowed chicken bone migration into the liver